Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT70N8V)

• DTT Name: Myeloid inhibitory C-type lectin-like receptor (CD371)
• Synonyms: MICL; Dendritic cell-associated lectin 2; DCAL2; DCAL-2; CLL1; CLL-1; C-type lectin-like molecule 1; C-type lectin domain family 12 member A
• Gene Name: CLEC12A
• DTT Type: Clinical trial target; [1]
• UniProt ID: CL12A_HUMAN
• TTD ID: T71205
• Sequence:
  MSEEVTYADLQFQNSSEMEKIPEIGKFGEKAPPAPSHVWRPAALFLTLLCLLLLIGLGVL
  ASMFHVTLKIEMKKMNKLQNISEELQRNISLQLMSNMNISNKIRNLSTTLQTIATKLCRE
  LYSKEQEHKCKPCPRRWIWHKDSCYFLSDDVQTWQESKMACAAQNASLLKINNKNALEFI
  KSQSRSYDYWLGLSPEEDSTRGMRVDNIINSSAWVIRNAPDLNNMYCGYINRLYVQYYHC
  TYKKRMICEKMANPVQLGSTYFREA
• Function: Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases.
• Reactome Pathway: Neutrophil degranulation (R-HSA-6798695)

Molecular Interaction Atlas (MIA) of This DTT

8 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CD123/CLL1 CAR-T Cells	DM45Z3P	Acute myeloid leukaemia	2A60	Phase 2/3	[1]
CLL1 CAR-T Cell	DMUOMBZ	Acute myeloid leukaemia	2A60	Phase 2/3	[1]
CAR-T cells targeting CLL1	DMCPM92	leukaemia	2A60-2B33	Phase 1/2	[2]
CLL1-specific gene-engineered T cells	DMCT917	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
CLL1-CD33 cCART cell therapy	DM5EM04	Acute myeloid leukaemia	2A60	Phase 1	[4]
CLT030	DM674MP	Acute myeloid leukaemia	2A60	Phase 1	[5]
KITE-222	DMPF49Z	Acute myeloid leukaemia	2A60	Phase 1	[6]
Tepoditamab	DMC84Y9	Acute myelogenous leukaemia	2A41	Phase 1	[7]

1 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
UCART-CLL1	DMT06MI	Multiple myeloma	2A83	Preclinical	[8]

References

• [1] ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
• [2] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [3] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [4] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [5] Clinical pipeline report, company report or official report of Cellerant Therapeutics.
• [6] Clinical pipeline report, company report or official report of Gilead
• [7] MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733.
• [8] Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.